Basal cell carcinoma
known and novel
Performance summary
| Top percentile | OR | 95% CI |
|---|---|---|
| 1% | 3.61 | 2.53-5.15 |
| 2% | 3.67 | 2.84-4.74 |
| 5% | 3.09 | 2.58-3.71 |
| 10% | 2.7 | 2.34-3.11 |
| 25% | 2.35 | 2.09-2.64 |
How to use this score page
- Start with P value and the main performance metrics above to judge whether this model is useful in this cohort.
- Use the top-percentile rows to see how strongly the score separates the upper PRS tail.
- Use the main Scores table to compare alternative models for the same trait when no preserved PheWAS follow-up is attached.
Flag guide: nominally significant passed the preserved release's nominal threshold; reversed effect means the observed direction ran opposite to the expected effect direction in the preserved evaluation.
Files and next steps
This release keeps the score metadata and performance summary for this model, but it does not preserve a rendered PheWAS result set or downloadable scan tables for it. Use the main Scores table to compare alternative models for the same trait, and see the Method page for cohort and metric definitions.
Related links and downloads
This release does not preserve direct weight links or PheWAS artifacts for this model. Use the main Scores table to compare alternative models for the same trait.